181 related articles for article (PubMed ID: 33359593)
1. Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study.
Mahmoudi H; Farid AS; Nili A; Dayani D; Tavakolpour S; Soori T; Teimourpour A; Isazade A; Abedini R; Balighi K; Daneshpazhooh M;
J Am Acad Dermatol; 2021 Apr; 84(4):1098-1100. PubMed ID: 33359593
[No Abstract] [Full Text] [Related]
2. Rituximab for the treatment of autoimmune subepidermal blistering diseases.
Riquelme-Mc Loughlin C; Estrach T; Morgado-Carrasco D; Fustà-Novell X; Riera-Monroig J; Iranzo P
Dermatol Ther; 2018 Sep; 31(5):e12687. PubMed ID: 30207027
[No Abstract] [Full Text] [Related]
3. Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients.
Kurihara Y; Yamagami J; Funakoshi T; Ishii M; Miyamoto J; Fujio Y; Kakuta R; Tanikawa A; Aoyama Y; Iwatsuki K; Ishii N; Hashimoto T; Nishie W; Shimizu H; Kouyama K; Amagai M
J Dermatol; 2019 Feb; 46(2):124-130. PubMed ID: 30585649
[TBL] [Abstract][Full Text] [Related]
4. Adverse outcome and severity of COVID-19 in patients with autoimmune bullous diseases: A historical cohort study.
Moghadam FS; Kianfar N; Dasdar S; Samii R; Farimani Z; Azar PM; Balighi K; Abedini R; Soori T; Farid AS; Mahmoudi H; Daneshpazhooh M
Dermatol Ther; 2022 Sep; 35(9):e15672. PubMed ID: 35768959
[TBL] [Abstract][Full Text] [Related]
5. [Autoimmune blistering skin diseases: recent advances].
Joly P
Presse Med; 2010 Oct; 39(10):1040-1. PubMed ID: 20692800
[No Abstract] [Full Text] [Related]
6. Rituximab and its use in autoimmune bullous disorders.
Daniel BS; Murrell DF; Joly P
Dermatol Clin; 2011 Oct; 29(4):571-5. PubMed ID: 21925000
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for autoimmune blistering diseases: recent studies, new insights.
Lunardon L; Payne AS
G Ital Dermatol Venereol; 2012 Jun; 147(3):269-76. PubMed ID: 22648328
[TBL] [Abstract][Full Text] [Related]
8. Protracted SARS-CoV-2 pneumonia with rituximab treatment: About two cases.
Gerber V; Velay A; Boehn L; Solis M; Kaeuffer C; Rougier E; Ursenbach A; Hansmann Y; Lefebvre N; Danion F; Ruch Y
J Med Virol; 2021 Jul; 93(7):4141-4144. PubMed ID: 33666242
[No Abstract] [Full Text] [Related]
9. Rituximab in treatment-resistant autoimmune blistering skin disorders.
Schmidt E; Bröcker EB; Goebeler M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):56-64. PubMed ID: 18270859
[TBL] [Abstract][Full Text] [Related]
10. Bullous Diseases.
Corbaux C; Joly P
Curr Probl Dermatol; 2018; 53():64-69. PubMed ID: 29131038
[TBL] [Abstract][Full Text] [Related]
11. Practice and Educational Gaps in Blistering Disease.
Ehsani-Chimeh N; Marinkovich MP
Dermatol Clin; 2016 Jul; 34(3):251-6. PubMed ID: 27363880
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil for the management of autoimmune bullous diseases.
Eskin-Schwartz M; David M; Mimouni D
Immunol Allergy Clin North Am; 2012 May; 32(2):309-15, vii. PubMed ID: 22560143
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous rituximab for autoimmune bullous diseases.
Riquelme-Mc Loughlin C; Iranzo P
Br J Dermatol; 2021 Oct; 185(4):870-871. PubMed ID: 34009646
[No Abstract] [Full Text] [Related]
14. The emerging role of rituximab in autoimmune blistering diseases.
Ahmed AR; Shetty S
Am J Clin Dermatol; 2015 Jun; 16(3):167-77. PubMed ID: 25791770
[TBL] [Abstract][Full Text] [Related]
15. [Linear IgA bullous dermatosis: a review].
Ingen-Housz-Oro S
Ann Dermatol Venereol; 2011 Mar; 138(3):214-20. PubMed ID: 21397151
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in refractory autoimmune bullous diseases.
Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
[TBL] [Abstract][Full Text] [Related]
17. Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions.
Alaibac M
Front Immunol; 2018; 9():810. PubMed ID: 29720979
[No Abstract] [Full Text] [Related]
18. Picture of the month. Chronic bullous dermatosis of childhood.
Sheehan M; Huddleston H; Mousdicas N
Arch Pediatr Adolesc Med; 2008 Jun; 162(6):581-2. PubMed ID: 18524750
[No Abstract] [Full Text] [Related]
19. COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review.
Bakasis AD; Mavragani CP; Boki KA; Tzioufas AG; Vlachoyiannopoulos PG; Stergiou IE; Skopouli FN; Moutsopoulos HM
J Autoimmun; 2021 Sep; 123():102687. PubMed ID: 34311142
[TBL] [Abstract][Full Text] [Related]
20. [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases].
Kasperkiewicz M; Zillikens D
Hautarzt; 2007 Feb; 58(2):115-6, 118-21. PubMed ID: 17237928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
